TNFSF13B and B-cell chronic lymphocytic leukemia: This triple combination of belimumab, a BAFF-neutralizing antibody which is FDA-approved for systemic lupus erythematosus (SLE), venetoclax and rituximab prevented BAFF-induced venetoclax resistance in CLL in vitro [76].